Adsorption of antisense oligonucleotides targeting malarial topoi-somerase II on cationic nanoemulsions optimized by a full factorial design

Current Topics in Medicinal Chemistry

Volumn 14, Issue 9, 2014, Pages 1161-1171

  Bruxel, Fernanda ^a,b   Bochot, Amélie ^b   Diel, Dirnete ^a   Wild, Luisa ^a   Carvalho, Edison L S ^c   Cojean, Sandrine ^d   Loiseau, Philippe M ^d   Fattal, Elias ^b   Teixeira, Helder F ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d UNIVERSITÉ PARIS SUD   (France)

Author keywords

Adsorption isotherms; Antisense oligonucleotide; Cationic nanoemulsions; Factorial design; Plasmodium falciparum topoisomerase II

Indexed keywords

1, 2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANTISENSE OLIGONUCLEOTIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DRUG CARRIER; OLEYLAMINE; PHOSPHATIDYLCHOLINE; PHOSPHODIESTER; PHOSPHORIC ACID DERIVATIVE; PHOSPHOROTHIOIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CATION; EMULSION; NANOMATERIAL;

ADSORPTION; ARTICLE; CATIONIC NANOEMULSIONS; CONTROLLED STUDY; DRUG FORMULATION; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH INHIBITION; HEMOLYSIS; HUMAN; HUMAN CELL; MALARIA; NANOEMULSION; NONHUMAN; NORMAL HUMAN; PHYSICAL CHEMISTRY; PLASMODIUM FALCIPARUM; TRANSMISSION ELECTRON MICROSCOPY; ULTRAFILTRATION; ZETA POTENTIAL; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; DRUG SENSITIVITY; EMULSION; ENZYMOLOGY; ERYTHROCYTE; METABOLISM; MICROBIOLOGY; SURFACE PROPERTY;

ADSORPTION; CATIONS; DNA TOPOISOMERASES, TYPE II; DRUG DESIGN; EMULSIONS; ERYTHROCYTES; MICROSCOPY, ELECTRON, TRANSMISSION; NANOSTRUCTURES; OLIGONUCLEOTIDES, ANTISENSE; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; SURFACE PROPERTIES;

EID: 84903718080     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026614666140329230835     Document Type: Article

References (41)

1. World Health Organization, W. H. Malaria. http://www.who.int/topics/malaria/en/ (Accessed May 28, 2013).
2. Na-Bangchang, K.; Congpuong, K. Current malaria status and distribution of drug resistance in East and Southeast Asia with special focus to Thailand. Tohoku J. Exp. Med., 2007, 211(2), 99-113.
3. Witkowski, B.; Lelievre, J.; Barragan, M. J.; Laurent, V.; Su, X. Z.; Berry, A.; Benoit-Vical, F. Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism. Antimicrob. Agents Chemother., 2010, 54(5), 1872-1877.
4. Baker, M. T.; Naguib, M. Propofol: the challenges of formulation. Anesthesiology, 2005, 103(4), 860-876.
5. Föger, F.; Noonpakdee, W.; Loretz, B.; Joojuntr, S.; Salvenmoser, W.; Thaler, M.; Bernkop-Schnürch, A. Inhibition of malarial topoi-somerase II in Plasmodium falciparum by antisense nanoparticles. Int. J. Pharm., 2006, 319(1-2), 139-146.
6. Kanagaratnam, R.; Misiura, K.; Rebowski, G.; Ramasamy, R. Malaria merozoite surface protein antisense oligodeoxynucleotides lack antisense activity but function as polyanions to inhibit red cell invasion. Int. J. Biochem. Cell Biol., 1998, 30(9), 979-985.
7. Noonpakdee, W.; Pothikasikorn, J.; Nimitsantiwong, W.; Wilairat, P. Inhibition of Plasmodium falciparum proliferation in vitro by an-tisense oligodeoxynucleotides against malarial topoisomerase II. Biochem. Biophys. Res. Commun., 2003, 302(4), 659-664.
8. Wanidworanun, C.; Nagel, R. L.; Shear, H. L. Antisense oligonu-cleotides targeting malarial aldolase inhibit the asexual erythrocytic stages of Plasmodium falciparum. Mol. Biochem. Parasitol., 1999, 102(1), 91-101.
9. Barker, R. H., Jr.; Metelev, V.; Rapaport, E.; Zamecnik, P. Inhibition of Plasmodium falciparum malaria using antisense oligode-oxynucleotides. Proc. Natl. Acad. Sci. USA, 1996, 93(1), 514-518.
10. Fattal, E.; Barratt, G. Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. Br. J. Pharmacol., 2009, 157(2), 179-194.
11. Bruxel, F.; Cojean, S.; Bochot, A.; Teixeira, H.; Bories, C.; Loiseau, P. M.; Fattal, E. Cationic nanoemulsion as a delivery sys tem for oligonucleotides targeting malarial topoisomerase II. Int. J. Pharm., 2011, 416(2), 402-409.
12. Teixeira, H.; Rosilio, V.; Laigle, A.; Lepault, J.; Erk, I.; Scherman, D.; Benita, S.; Couvreur, P.; Dubernet, C. Characterization of oli-gonucleotide/lipid interactions in submicron cationic emulsions: influence of the cationic lipid structure and the presence of PEG-lipids. Biophys. Chem., 2001, 92(3), 169-181.
13. Hagigit, T.; Abdulrazik, M.; Orucov, F.; Valamanesh, F.; Lambert, M.; Lambert, G.; Behar-Cohen, F.; Benita, S. Topical and intravit-reous administration of cationic nanoemulsions to deliver antisense oligonucleotides directed towards VEGF KDR receptors to the eye. J. Controlled Release, 2010, 145(3), 297-305.
14. Teixeira, H.; Dubernet, C.; Chacun, H.; Rabinovich, L.; Boutet, V.; Deverre, J. R.; Benita, S.; Couvreur, P. Cationic emulsions improves the delivery of oligonucleotides to leukemic P388/ADR cells in ascite. J. Control. Release, 2003, 89(3), 473-482.
15. Teixeira, H.; Dubernet, C.; Puisieux, F.; Benita, S.; Couvreur, P. Submicron cationic emulsions as a new delivery system for oli-gonucleotides. Pharm. Res. 1999, 16(1), 30-36.
16. Teixeira, H.; Dubernet, C.; Rosilio, V.; Laigle, A.; Deverre, J. R.; Scherman, D.; Benita, S.; Couvreur, P. Factors influencing the oligonucleotides release from O-W submicron cationic emulsions. J. Control. Release, 2001, 70(1-2), 243-255.
17. Hagigit, T.; Nassar, T.; Behar-Cohen, F.; Lambert, G.; Benita, S. The influence of cationic lipid type on in-vitro release kinetic profiles of antisense oligonucleotide from cationic nanoemulsions. Eur. J. Pharm. Biopharm., 2008, 70(1), 248-259.
18. Trimaille, T.; Chaix, C.; Pichot, C.; Delair, T. Polymer functional-ized submicrometric emulsions as potential synthetic DNA vectors. J. Colloid Interface Sci., 2003, 258(1), 135-145.
19. Martini, E.; Fattal, E.; de Oliveira, M. C.; Teixeira, H. Effect of cationic lipid composition on properties of oligonucleo-tide/emulsion complexes: Physico-chemical and release studies. Int. J. Pharm., 2008, 352(1-2), 280-286.
20. Montgomery, D. C., Design and Analysis of Experiments. In 3 ed.; Wiley: New York, 1991; pp 228-301.
21. Sucker, H., Methoden zum Planen und Auswerten von Versuchen. I. Factorial design, eine Einführung. In APV-Informationsdienst: 1971; pp 52-68.
22. Mergny, J. L.; Lacroix, L.; Han, X.; Leroy, J. L.; Hélène, C. Intramolecular Folding of Pyrimidine Oligodeoxynucleotides into an i-DNA Motif. J. Am. Chem. Soc., 1995, 117(35), 8887-8898.
23. Fraga, M.; Bruxel, F.; Lagranha, V. L.; Teixeira, H. F.; Matte, U. Influence of phospholipid composition on cationic emulsions/DNA complexes: physicochemical properties, cytotoxicity, and transfec-tion on Hep G2 cells. Int. J. Nanomedicine, 2011, 6, 2213-2220.
24. Bruxel, F.; Guterres, S. S.; Teixeira, H. F. Validation of a spectro-photometric method to estimate the adsorption on nanoemulsions of an antimalarial oligonucleotide. Quim. Nova, 2011, 34(9), 1643-1646.
25. Trager, W.; Jensen, J. B. Human malaria parasites in continuous culture. Science, 1976, 193(4254), 673-675.
26. Lambros, C.; Vanderberg, J. P. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol., 1979, 65(3), 418-420.
27. Rabinovich-Guilatt, L.; Dubernet, C.; Gaudin, K.; Lambert, G.; Couvreur, P.; Chaminade, P. Phospholipid hydrolysis in a pharmaceutical emulsion assessed by physicochemical parameters and a new analytical method. Eur. J. Pharm. Biopharm., 2005, 61(1-2), 69-76.
28. Heurtault, B.; Saulnier, P.; Pech, B.; Proust, J. E.; Benoit, J. P. Physico-chemical stability of colloidal lipid particles. Biomaterials, 2003, 24(23), 4283-4300.
29. Rabinovich-Guilatt, L.; Couvreur, P.; Lambert, G.; Dubernet, C. Cationic vectors in ocular drug delivery. J. Drug Targeting, 2004, 12(9-10), 623-633.
30. Simberg, D.; Weisman, S.; Talmon, Y.; Barenholz, Y. DOTAP (and Other Cationic Lipids): Chemistry, Biophysics, and Transfec-tion. Crit. Rev. Ther. Drug Carrier Syst., 2004, 21(4), 257-317.
31. Washington, C. Stability of lipid emulsions for drug delivery. Adv. Drug Delivery Rev., 1996, 20(2-3), 131-145.
32. Guo, C.; Gemeinhart, R. A. Understanding the adsorption mechanism of chitosan onto poly(lactide-co-glycolide) particles. Eur. J. Pharm. Biopharm., 2008, 70(2), 597-604.
33. P. J., Martin's physical pharmacy and pharmaceutical sciences: physical chemical and biopharmaceutical principles in the pharmaceutical sciences. 5 ed.; Lippincott Williams & Wilkins: Philadelphia, 2006; pp.795
34. Achak, M.; Hafidi, A.; Ouazzani, N.; Sayadi, S.; Mandi, L. Low cost biosorbent banana peel for the removal of phenolic compounds from olive mill wastewater: kinetic and equilibrium studies. J. Hazard. Mater., 2009, 166(1), 117-125.
35. Klang, V.; Matsko, N. B.; Valenta, C.; Hofer, F. Electron microscopy of nanoemulsions: an essential tool for characterisation and stability assessment. Micron, 2012, 43(2-3), 85-103.
36. Chevaillier, P. Étude au microscope électronique de l'interaction de l'acide désoxyribonucléique et des polyamines. Exp. Cell Res., 2004, 58(2-3), 213-224.
37. Tarahovsky, T. S.; Khusainova, R. S.; Gorelov, A. V.; Nicolaeva, T. I.; Deev, A. A.; Dawson, A. K.; Ivanitsky, G. R. DNA initiates polymorphic structural transitions in lecithin. FEBS Lett., 1996, 390(2), 133-136.
38. Lasch, J. Interaction of detergents with lipid vesicles. Biochim. Biophys. Acta 1995, 1241(2), 269-292.
39. Pinnaduwage, P.; Schmitt, L.; Huang, L. Use of a quaternary ammonium detergent in liposome mediated DNA transfection of mouse L-cells. Biochim. Biophys. Acta, 1989, 985(1), 33-37.
40. Senior, J. H.; Trimble, K. R.; Maskiewicz, R. Interaction of positively-charged liposomes with blood: implications for their application in vivo. Biochim. Biophys. Acta, 1991, 1070(1), 173-179.
41. Amin, K.; Dannenfelser, R. M. In vitro hemolysis: guidance for the pharmaceutical scientist. J. Pharm. Sci., 2006, 95(6), 1173-1176.